Mirum Pharmaceuticals, Inc.
HealthcareNASDAQ:MIRM · NASDAQ Global Market
-$0.20 today
Vol 0.55M · Avg 0.97M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-7.4%
avg -26.2%
ROIC
-3.5%
avg -30.6%
ROA
-2.8%
avg -27.5%
Analysis
ROA is currently the strongest return metric at -2.8% versus its period average of -27.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher Peetz | Chief Executive Officer & Director | $1.83M | — | 47 | $194,309.00 | 0.39% |
Peter Radovich | Chief Operating Officer & President | $1.16M | — | 48 | $57,260.00 | 0.11% |
Joanne J. Quan | Chief Medical Officer | $1.00M | — | 62 | $18,864.00 | 0.04% |
Eric H. Bjerkholt | Chief Financial Officer | $1.00M | — | 66 | $47,181.00 | 0.09% |
Lara Longpre | Chief Development Officer | $678,200.00 | — | 56 | $104,407.00 | 0.21% |
Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations | — | — | — | — | — |
Jean-Luc Girardet | Chief Technical Officer | — | — | — | — | — |
Vinita Kumar | Senior Vice President of Quality | — | — | — | — | — |
Meredith Kiernan | Senior Director of Global Corporate Communications | — | — | — | — | — |
Erin Campany | Chief People Officer | — | — | 58 | — | — |
Douglas T. Sheehy | Chief Legal Officer & Secretary | — | — | 59 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$9.00M
Sells
49
$35.09M
Net Sentiment
$26.09M
Net selling
Most Active
Peetz Christopher
12 transactions
1–10 of 50
Analysis
Insiders reported 1 buys worth $9.00M and 49 sells worth $35.09M over the last 12 months. That adds up to net selling of $26.09M. Peetz Christopher was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | +47.5% (8yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +47.5% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Belite Bio, Inc
NASDAQ:BLTE
$5.54B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.12B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$4.84B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
Telix Pharmaceuticals Limited
NASDAQ:TLX
$3.24B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.90B
Who manages MIRM?
Mirum Pharmaceuticals, Inc. (MIRM) lists 11 active executives. The top listed executive is Lara Longpre, Chief Development Officer.
Are MIRM insiders buying or selling?
Recent insider activity shows net buying of $1.31M.
Explore More
Continue the stock analysis
Jump to another research area for this company.